Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00857532 |
Recruitment Status :
Completed
First Posted : March 6, 2009
Results First Posted : March 11, 2013
Last Update Posted : March 11, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson's Disease | Drug: florbetapir F 18 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 31 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Diagnostic |
Official Title: | A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | November 2011 |
Actual Study Completion Date : | November 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Normal cognitive performance
Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
|
Drug: florbetapir F 18
10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Other Names:
|
Experimental: Mild cognitive deficits
Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
|
Drug: florbetapir F 18
10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Other Names:
|
Experimental: Severe cognitive impairment
Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
|
Drug: florbetapir F 18
10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Other Names:
|
- Mean Cortical Amyloid Burden [ Time Frame: 50-60 min after injection ]Standardized uptake value ratios (SUVR) were calculated and compared between subjects with PD and controls. Subjects with Parkinson's Disease (PD) were stratified into one of three groups based on performance on the age and education adjusted Mattis Dementia Rating Scale (DRS-2). The age and education adjusted DRS-2 ranges from 0 (lowest cognitive function) to 20 (highest cognitive function). SUVR is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum. SUVR values higher than 1 indicate greater amyloid burden in the predefined cortical regions as compared to cerebellum whereas scores less than 1 indicate the opposite. This outcome measure only reports data from the subjects analyzed in this study, the data from normal controls was obtained from a pre-existing database and is not reported here.
- Correlation Between Global Amyloid Burden and Clinical Measures of Cognitive Decline. [ Time Frame: 50-60 min after injection ]Correlation between amyloid burden (global florbetapir SUVR) and cognitive decline (DRS-2 score) was determined using Spearman's rank order correlation method where SUVR was the dependent variable and the DRS-2 score was the independent variable. This analysis was performed for total DRS-2 score and the five DRS-2 subscale scores. The subscales (score range) are: Attention (0-37), Initiation/Perseveration (0-37), Construction (0-6), Conceptualization (0-39) and Memory (0-25). The total DRS-2 score is the sum of the subscale scores and ranges from 0-144. Higher DRS-2 scores indicate greater cognitive function.
- Correlation of Florbetapir SUVR With CSF Biomarker Values [ Time Frame: 50-60 min after injection ]Correlation between amyloid burden (florbetapir SUVR) and cerebrospinal fluid (CSF) biomarker values (amyloid beta, tau and phospho-tau) was determined using Spearman's rank order correlation in a subset of subjects undergoing CSF analysis where SUVR was the dependent variable and CSF biomarker values were the independent variables.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Subjects may be enrolled if they (inclusion criteria):
- Are males or females ≥60 years of age
- Meet research diagnostic criteria for Parkinson's disease:
-
Diagnosis of a parkinsonian syndrome
- Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in speed and amplitude of repetitive actions)
- At least one of the following: muscle rigidity, rest tremor, postural instability not due to visual, vestibular, cerebellar or proprioceptive causes
-
Supportive criteria for diagnosis of PD (two or more required)
- Unilateral onset of symptoms and persistent asymmetry
- Rest tremor present
- Progressive illness
- Excellent response to levodopa with dyskinesias
- Levodopa response for 5 years or more
- Clinical course of 10 years or more
- Have the ability to lie flat and tolerate a 10 minute PET scan.
Exclusion Criteria:
-
Subjects may not be enrolled if any of the following are present (exclusion criteria):
- History of repeated strokes, repeated head injury, definite encephalitis
- Use of neuroleptics at onset of symptoms
- Sustained remission
- Strictly unilateral feature persisting > three years after onset
- Significant supranuclear gaze palsy
- Cerebellar, pyramidal and early severe autonomic findings
- Early severe dementia suggesting a diagnosis of dementia with Lewy bodies (DLB)
- Imaging study showing structural abnormality that could explain parkinsonism
- Negative response to an adequate levodopa trial
- Current clinically significant psychiatric disease that prohibits providing informed consent or participation in the study
- Current clinically significant endocrine or metabolic disease, pulmonary,
- Women of childbearing potential who are not two or more years post menopausal or surgically sterilized
- Have received any investigational medications, or have participated in a trial with investigational medications within the last 30 days

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00857532
United States, Pennsylvania | |
Research Site | |
Philadelphia, Pennsylvania, United States, 19104 |
Study Director: | Chief Medical Officer | Avid Radiopharmaceuticals |
Responsible Party: | Avid Radiopharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00857532 |
Other Study ID Numbers: |
18F-AV-45-A12 5R43NS063607-02 ( U.S. NIH Grant/Contract ) |
First Posted: | March 6, 2009 Key Record Dates |
Results First Posted: | March 11, 2013 |
Last Update Posted: | March 11, 2013 |
Last Verified: | February 2013 |
amyloid burden Parkinson's disease florbetapir PET amyloid PET imaging |
Parkinson Disease Amyloidosis Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases Proteostasis Deficiencies Metabolic Diseases |